Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + nonpegylated liposomal doxorubicin
- Development stage
- Unknown
- Lead developer
- Sopherion Therapeutics
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This drug is a combination of two chemotherapeutic agents used primarily in the treatment of breast cancer. Docetaxel is a taxane that promotes microtubule assembly and inhibits their disassembly, leading to cell cycle arrest and apoptosis. Nonpegylated liposomal doxorubicin is an anthracycline antibiotic encapsulated in a conventional (non-PEG) liposome formulation, which intercalates DNA strands, inhibits topoisomerase II, and generates free radicals causing cytotoxicity. The combination leverages the distinct mechanisms of both drugs for synergistic antitumor activity with manageable toxicity profiles. This regimen has been studied as first-line therapy for metastatic breast cancer and shows high response rates[1][2][3]. Liposomal encapsulation aims to reduce cardiac toxicity compared to conventional doxorubicin.
- Other names
- docetaxel and nonpegylated liposomal doxorubicindocetaxel plus nonpegylated liposomal doxorubicin
02
Targets
TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on docetaxel + nonpegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + nonpegylated liposomal doxorubicin.